Journal of Clinical Oncology, Vol 13, 2324-2329, Copyright © 1995 by American Society of Clinical Oncology
Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer
M Wiesenfeld, MJ O'Connell, HS Wieand, NJ Gonchoroff, JH Donohue, RJ Fitzgibbons Jr, JE Krook, JA Mailliard, JB Gerstner and R Pazdur
Cedar Rapids Oncology Project Community Clinical Oncology Program, IA, USA.
PURPOSE: The primary goal of this study was to assess the effectiveness of
interferon gamma (IFN-gamma) to prevent tumor relapse following potentially
curative surgery in patients with high-risk colon cancer. A secondary goal
was to determine the effect of IFN-gamma on immune function and to
correlate alterations in immune parameters with survival. PATIENTS AND
METHODS: Three to 4 weeks after undergoing resection of all known malignant
disease, 99 patients with stage II, III, or IV colon cancer were randomly
assigned to receive IFN-gamma 0.2 mg total dose by subcutaneous injection
daily for 6 months or observation. Serial assessment of human leukocyte
antigen (HLA)-DR expression and Fc receptors on peripheral-blood monocytes
was conducted in 24 patients who received IFN-gamma and 27 control
patients. RESULTS: With a median follow-up duration of 59 months in
patients still alive, there was evidence of a detrimental effect on time to
relapse (P = .03) among patients who received IFN-gamma. There was no
significant difference in patient survival (P = .12). This study has
sufficient power to rule out a 25% reduction in death rate for patients who
received IFN-gamma (P < .05). Significant enhancement of immune function
was observed in patients treated with IFN-gamma as measured by HLA-DR
expression (P < .01) and Fc receptors (P < .001) on peripheral- blood
monocytes. CONCLUSION: This study effectively rules out any clinically
meaningful benefit for IFN-gamma as surgical adjuvant treatment for
patients with high-risk colon cancer. Although significant enhancement of
nonspecific immune function was seen with this dosage administration
schedule of IFN-gamma, this was not associated with any demonstrable
antitumor effect.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al.
Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study
J. Clin. Oncol.,
May 1, 2004;
22(9):
1572 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. de Metz, J. A. Romijn, E. Endert, M. T. Ackermans, G. J. Weverling, O. R. Busch, L. Th. de Wit, D. J. Gouma, I. J. M. t. Berge, and H. P. Sauerwein
Interferon-{gamma} increases monocyte HLA-DR expression without effects on glucose and fat metabolism in postoperative patients
J Appl Physiol,
February 1, 2004;
96(2):
597 - 603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Allegra, A. L. Parr, L. E. Wold, M. R. Mahoney, D. J. Sargent, P. Johnston, P. Klein, K. Behan, M. J. O'Connell, R. Levitt, et al.
Investigation of the Prognostic and Predictive Value of Thymidylate Synthase, p53, and Ki-67 in Patients With Locally Advanced Colon Cancer
J. Clin. Oncol.,
April 1, 2002;
20(7):
1735 - 1743.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al.
Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
J Natl Cancer Inst,
August 4, 1999;
91(15):
1295 - 1303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
